Jounce Therapeutics, Inc. JNCE
Day range unavailable
52-week range unavailable
- Market cap
- 101.59M
- Revenue (ttm)
- 82.00M
- Profit margin
- -62.10%
- Shares out
- 52.64M
- Forward P/E
- -1.83
- Beta
- 0.75
- Analysts
- Hold
- Price target
- 2.00 (+6.4%)
- Earnings date
- May 4, 2023
Key statistics
- Enterprise value
- -81.50M
- PEG ratio
- 0.00
- Price / sales
- 1.24
- Price / book
- 0.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.42M
- Total cash
- 189.54M
- Total debt
- 10.02M
- Return on equity
- -25.03%
- Short % of float
- 4.36%
- 50-day average
- 1.64
- 200-day average
- 1.93
Analyst view
Consensus: hold
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 4, 2023
Expected May 4, 2023. Consensus EPS estimate -0.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2023 | Mar 1, 2023 | -0.72 | — | — | — |
| Apr 5, 2023 | Dec 1, 2022 | 0.95 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.64 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.68 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.57 | — | — | — |
| Mar 2, 2022 | Dec 1, 2021 | -0.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 24, 2023 | SMBC Nikko | down | Outperform | Neutral |
| Feb 23, 2023 | Raymond James | down | Outperform | Market Perform |
| Jan 3, 2023 | Piper Sandler | main | — | Overweight |
| Nov 11, 2022 | Raymond James | down | Strong Buy | Outperform |
| Aug 31, 2022 | Raymond James | main | — | Strong Buy |
| Aug 5, 2022 | HC Wainwright & Co. | main | — | Buy |
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jouncetx.com
News
S&P 500 Down Over 1%; ThermoGenesis Shares Spike Higher 
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 - Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Stocks That Hit 52-Week Lows On Monday 
Stocks That Hit 52-Week Lows On Tuesday 
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022 
Stocks That Hit 52-Week Lows On Friday 
Earnings Scheduled For November 10, 2022 - Stocks That Hit 52-Week Lows On Monday
Your note
Sign in to keep a note on JNCE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLE HUGH M | Chief Operating Officer | Sale | Jan 9, 2023 | 110,082 |
| DRAPKIN KIMBERLEE COBLEIGH CPA | Chief Financial Officer | Sale | Jan 9, 2023 | 66,018 |
| HIGGONS JOHN DUNCAN | Director | Sale | Apr 14, 2021 | 9,713 |
| MURRAY RICHARD | Director | Sale | Apr 3, 2023 | 188,779 |
| PFEFFER CARY G | Director | Sale | Nov 11, 2021 | 0 |
| TANG KEVIN C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 13, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 9.70% | 5,106,341 | 9.60M | Dec 30, 2022 |
| Deep Track Capital, LP | 8.09% | 4,259,653 | 8.01M | Dec 30, 2022 |
| Cowen and Company, LLC | 6.93% | 3,647,430 | 6.86M | Dec 30, 2022 |
| Bank of America Corporation | 6.23% | 3,276,699 | 6.16M | Dec 30, 2022 |
| Blackrock Inc. | 4.89% | 2,571,456 | 4.83M | Dec 30, 2022 |
| Millennium Management Llc | 3.47% | 1,828,681 | 3.44M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.82% | 950,782 | 1.79M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.69% | 879,312 | 1.65M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.87% | 454,255 | 854.00K | Dec 30, 2022 |
| iShares Russell 2000 Value ETF | 0.84% | 438,387 | 824.17K | Feb 27, 2023 |
| Fidelity Small Cap Index Fund | 0.68% | 353,537 | 664.65K | Jan 30, 2023 |
| Fidelity Extended Market Index Fund | 0.33% | 173,075 | 325.38K | Feb 27, 2023 |